TBRG vs. RPTX, AGEN, OM, ADAG, CRDL, CTXR, RLMD, COYA, BDSX, and KNTE
Should you be buying TruBridge stock or one of its competitors? The main competitors of TruBridge include Repare Therapeutics (RPTX), Agenus (AGEN), Outset Medical (OM), Adagene (ADAG), Cardiol Therapeutics (CRDL), Citius Pharmaceuticals (CTXR), Relmada Therapeutics (RLMD), Coya Therapeutics (COYA), Biodesix (BDSX), and Kinnate Biopharma (KNTE). These companies are all part of the "medical" sector.
Repare Therapeutics (NASDAQ:RPTX) and TruBridge (NASDAQ:TBRG) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, earnings, risk, media sentiment, institutional ownership, profitability, community ranking, analyst recommendations and valuation.
85.1% of Repare Therapeutics shares are owned by institutional investors. Comparatively, 88.6% of TruBridge shares are owned by institutional investors. 28.5% of Repare Therapeutics shares are owned by company insiders. Comparatively, 3.6% of TruBridge shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
TruBridge has a net margin of -13.49% compared to TruBridge's net margin of -183.43%. Repare Therapeutics' return on equity of 10.33% beat TruBridge's return on equity.
TruBridge has higher revenue and earnings than Repare Therapeutics. TruBridge is trading at a lower price-to-earnings ratio than Repare Therapeutics, indicating that it is currently the more affordable of the two stocks.
Repare Therapeutics has a beta of 0.56, suggesting that its share price is 44% less volatile than the S&P 500. Comparatively, TruBridge has a beta of 0.63, suggesting that its share price is 37% less volatile than the S&P 500.
In the previous week, Repare Therapeutics had 2 more articles in the media than TruBridge. MarketBeat recorded 5 mentions for Repare Therapeutics and 3 mentions for TruBridge. TruBridge's average media sentiment score of 0.76 beat Repare Therapeutics' score of 0.00 indicating that Repare Therapeutics is being referred to more favorably in the media.
Repare Therapeutics received 31 more outperform votes than TruBridge when rated by MarketBeat users. However, 100.00% of users gave TruBridge an outperform vote while only 60.71% of users gave Repare Therapeutics an outperform vote.
Repare Therapeutics presently has a consensus price target of $17.33, suggesting a potential upside of 415.87%. TruBridge has a consensus price target of $18.50, suggesting a potential upside of 128.68%. Given TruBridge's higher probable upside, equities analysts clearly believe Repare Therapeutics is more favorable than TruBridge.
Summary
Repare Therapeutics beats TruBridge on 9 of the 17 factors compared between the two stocks.
Get TruBridge News Delivered to You Automatically
Sign up to receive the latest news and ratings for TBRG and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TBRG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
TruBridge Competitors List
Related Companies and Tools
